Abstract
A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adrenocorticotropic Hormone / administration & dosage
-
Adrenocorticotropic Hormone / therapeutic use
-
Adult
-
Clinical Trials as Topic
-
Female
-
Humans
-
Injections, Intramuscular
-
Injections, Intravenous
-
Male
-
Methylprednisolone / administration & dosage
-
Methylprednisolone / therapeutic use*
-
Middle Aged
-
Multiple Sclerosis / drug therapy*
-
Random Allocation
-
Recurrence
-
Time Factors
Substances
-
Adrenocorticotropic Hormone
-
Methylprednisolone